I am co-founder of Nami Therapeutics and Associate Professor of Pharmaceutics at the University of Connecticut. I am the inventor of the key technologies that Nami Therapeutics is advancing. My research is focused on nanoparticle-based drug delivery platforms for improving cancer diagnosis and therapy.
Nami Therapeutics Corp is revolutionizing the science of nanotechnology by employing a targeted delivery platform to improve cancer patient survival. The limitations of current cancer nanomedicines include low tumor delivery efficiency, no significant benefit in treatment efficacy, cancer relapse when stopping treatment, and challenges in the manufacturing process. Our experienced team is focused on tumor-specific nanoparticle platforms to largely improve delivery efficiency, treatment efficacy and product safety. One novel product is radiotherapeutic nanoparticles containing the beta particle-emitting isotope holmium-166 (166Ho) for the treatment of peritoneal metastasis through intraperitoneal (i.p.) administration. The 166Ho nanoparticles are produced by a neutron activation process that minimizes the handling of these highly radioactive nanoparticles. We have demonstrated the predominant accumulation of 166Ho nanoparticles in tumors after i.p. administration to ovarian tumor-bearing mice, resulting in a reduction in tumor burden and prolonged survival. There are no current FDA approved radiotherapeutics for treating peritoneal metastasis. Regulatory approval of the 166Ho-nanoparticle product is anticipated through the Investigational Device Exemption (IDE) route. It is also expected that 166Ho-nanoparticles will be eligible for FDA Humanitarian Device approval.